Astrazeneca Stock Is Having A Solid Turnaround. I Share My Buy Price. $AZN
1 extracted signal · 0 resolved · 1 still active
Confident Compounding with Cory CramerIndependent analyst profile- Source published
- 20 Oct 2026, 13:27 UTC
- Recorded by Tahlil Plus
- 20 Oct 2026, 19:25 UTC
AI-generated source summary
The analysis focuses on AstraZeneca PLC (AZN), a pharmaceutical company. The historical data suggests a strong upward trend in earnings growth, with a consistent 10-11% annual growth rate over the past decade, and a CAGR of 18.65% in EPS. The stock price has largely followed this earnings growth trajectory, with significant appreciation observed. Despite some historical dips, particularly in 2008 and during the pandemic, the long-term trend remains robust. Current valuation metrics and forward analyst estimates for EPS suggest continued growth. The stock's price-to-earnings (P/E) ratio is currently 16.53x. The company's debt-to-capital ratio is manageable at 31.96%, and its market cap stands at $256.53B. Based on the historical earnings growth and forward estimates, the target for the stock is projected to be around $190.65, with a fail bound at $128.95, indicating a bullish outlook with a reasonable margin of safety.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Confident Compounding with Cory Cramer
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.